Venetoclax (ABT-199) is an important anti-cancer drug jointly developed by Swiss pharmaceutical company Roche and US biotechnology company AbbVie. As the world's first Bcl-2 selective inhibitor, venetoclax targets the BCL-2 protein in cancer cells, inducing apoptosis in tumor cells and thereby achieving tumor treatment. On April 11, 2016, ABT-199 received marketing approval from the US FDA for the treatment of chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and acute myeloid leukemia (AML). In December 2020, venetoclax was launched in China and is now covered by my country's medical insurance, providing patients with a new treatment option.

Indications of ABT-199

1. Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma Venetoclax tablets are indicated for the treatment of adults with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL).

2. Acute Myeloid Leukemia: Venetoclax tablets, in combination with azabitan, decitabine, or low-dose cytarabine, are indicated for the treatment of newly diagnosed acute myeloid leukemia (AML) in adults aged 75 years and older, or in patients with comorbidities that preclude intensive induction chemotherapy.

Adverse Reactions of ABT-199

In CLL/SRL, the most common adverse reactions (>20%) are: neutropenia, thrombocytopenia, anemia, diarrhea, nausea, upper respiratory tract infection, cough, musculoskeletal pain, fatigue, and edema. In AML, the most common adverse reactions are: nausea, diarrhea, thrombocytopenia, constipation, neutropenia, febrile neutropenia, fatigue, vomiting, edema, fever, pneumonia, dyspnea, bleeding, anemia, rash, abdominal pain, sepsis, musculoskeletal pain, dizziness, cough, oropharyngitis, pain, and hypotension.

Contraindications of ABT-199

Concomitant use of potent Cyp3A inhibitors is contraindicated in the initiation and acceleration phases of CLL/SLL patients.